Roche manufacturing restructure means EU, US jobs cuts
November 13, 2015Manufacturing and Production, Medical Communications Roche, job cuts, job losses, manufacturing, production, redundancies, restructure
Roche has announced plans to restructure its manufacturing network for small molecules, in a move that will see it mothball …
Boehringer cuts R&D budget to €11bn to focus on collaborations
November 13, 2015Medical Communications, Research and Development Boehringer Ingelheim
Boehringer Ingelheim has launched its new research and development strategy, committing €11 billion to R&D over the next five years. …
The ‘Pharmasaurus’ aims to evolve into a leader in the digital age
November 12, 2015Medical Communications, Research and Development Bayer, Roche, digital health, pharma
Pharma’s new-found willingness to embrace all aspects of the digital age, and use it both to its advantage and that …
Antibiotic prescriptions falling across England, but higher in deprived areas
November 12, 2015Medical Communications Antibiotics, prescribing
New data reveals that while antibiotic prescriptions have fallen across England in the last three years, struggling GP practices in …
Three new drugs approved for use in Scotland
November 12, 2015Sales and Marketing Scottish Medicines Consortium
The Scottish Medicines Consortium (SMC) has given the go-ahead for the use of several drugs on the NHS in Scotland. …
GSK ready for lupus drug push
November 12, 2015Manufacturing and Production, Research and Development, Sales and Marketing Benlysta, GSK, Lupus, SLE, belimumab, systemic lupus erythematosus
Having presented positive late-stage results for a new formulation of its inflammatory drug Benlysta, GSK says it will file supplementary …
Merck achieves 7% sales growth in Q3 2015
November 12, 2015Sales and Marketing Merck, Rebif, financial results
German pharma group Merck has earned a 7% bump in its sales, and a 10% boost in earnings before deductions, …
MSF launches global action against GSK and Pfizer over pneumonia vaccine price
November 12, 2015Manufacturing and Production, Sales and Marketing Doctors Without Borders, GSK, MSF, Médecins Sans Frontières, Pfizer, Synflorix, pneumococcal vaccine, pneumonia, prevenar 13, vaccines
International medical aid charity Médecins Sans Frontières/Doctors Without Borders (MSF) is taking action against GlaxoSmithKline and Pfizer, calling on the …
LEO Pharma buys dermatology portfolio from Astellas
November 12, 2015Sales and Marketing Astellas, LEO Pharma, acquisitions, dermatology, mergers
LEO Pharma, the speciality dermatology firm, is looking to expand its presence in the therapy area by buying Astellas’ portfolio …
Astellas to acquire Ocata Therapeutics in $379m buyout
November 11, 2015Research and Development, Sales and Marketing Astellas, Ocata, Stem cells, cell therapy, ophthalmology
Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
UK ‘lacks the skills’ for future drug development, ABPI warns
November 11, 2015Business Services, Research and Development ABPI, Jobs, careers, recruitment, skills gap
A shortage of skilled professionals threatens to undermine research and development of new medicines in the UK and prevent growth …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
Lilly/Incyte RA drug bests Humira in Phase III trial
November 10, 2015Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis
Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …
ABPI welcomes science budget inquiry findings
November 10, 2015Manufacturing and Production, Research and Development ABPI, Comprehensive Spending Review
The UK pharma trade body, the ABPI, has welcomed the findings of the Science and Technology Committee’s inquiry into the …
All Party Parliamentary Group for Life Sciences CSR letter to the Chancellor, Business Secretary and Science Ministers
November 10, 2015Manufacturing and Production, Research and Development Chancellor, Comprehensive Spending Review, George Osborne
Dear Mr Osborne,Ahead of the forthcoming Comprehensive Spending Review I am sure you will have received many letters from across …
Janssen buys licence to diabetes and obesity drugs from Hanmi
November 10, 2015Manufacturing and Production, Research and Development Janssen, diabetes, hanmi
Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity. …
FDA warnings create woe for Indian drugmakers
November 10, 2015Manufacturing and Production CGMP, Dr Reddy's, Dr. Reddy's, FDA, India, Sun Pharma, manufacturing, production
Recent enforcement action has taken its toll on the fortunes of several Indian pharmaceutical manufacturers, with Sun Pharmaceuticals and Dr. …
Sanofi Pasteur ‘actively exploring’ universal flu vaccine
November 10, 2015Manufacturing and Production, Research and Development SEEK, Sanofi Pasteur, influenza, universal flu vaccine
Sanofi Pasteur is developing a universal, cross-reactive antigen against seasonal and pandemic influenza, the company has revealed.The French firm presented its …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
